GlycoMimetics Investor Relations Material

GlycoMimetics Inc. is a clinical-stage biotechnology company focused on developing novel therapies that target the role of sugars in disease, particularly in the areas of cancer and inflammatory diseases. The company’s drug candidates are designed to block specific carbohydrate interactions that contribute to disease progression, with a focus on improving treatment outcomes for patients with blood cancers and rare diseases. GlycoMimetics develops small-molecule glycomimetic compounds that are intended to disrupt key biological processes in various disease states. The company is headquartered in Rockville, Maryland, and its shares are listed on the NASDAQ.